WHWK:NASDAQ, Whitehawk Therapeutics, Inc.
WHWK stock overview
Whitehawk Therapeutics, Inc. (WHWK:NASDAQ) closed at $3.06 on November 13, 2026,
down 0.33% on the day.
The stock trades 44.3% below its 52-week high of $5.50
and 55.3% above its 52-week low of $1.97.
Over the past year, it gained 44.3%.
Whitehawk Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $3.06
- Day change
- -0.33%
- Volume
- 212,182
- Average volume
- 341,092
- Market cap
- 180M+
- 52-week range
- $1.97 – $5.50
- 50-day average
- $3.57
- 200-day average
- $3.85
Price action over the past year
In 252 trading sessions since November 13, 2025, WHWK closed higher on 120 days (48%).
Its best day was May 13, 2026 (+25.77%) and its worst was March 27, 2026 (-11.48%).
The stock moved 10% or more in a single session 6 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
WHWK news
-
Nov 12, 2026:
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
-
Nov 9, 2026:
Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
-
Oct 7, 2026:
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
-
Oct 1, 2026:
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
-
Sep 14, 2026:
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
-
Sep 10, 2026:
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
-
Sep 2, 2026:
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
-
Aug 28, 2026:
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
About Whitehawk Therapeutics, Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
Similar stocks
Find more stocks like WHWK with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.